phrykt

MapLight Therapeutics, Inc. (MPLT): who owns it and who trades it

As of Nov 16, 2026, MPLT insiders reported 145 open-market sales worth $30.2M and 10 purchases worth $66.2M in the last 12 months, with 66% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher A. Kroeger (CEO), with $13.1M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling MapLight Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MPLT

107 funds and institutions reported MPLT shares worth $946M at the end of Q2 2026, about 62% of the company. The largest holder is Novo Holdings A/s with 8.7%.

Funds and institutions (13F) 62%Everyone else 38%

10 largest owners, by share of the company

Novo Holdings A/s8.7%
Fcpm III Services B.v.7.6%
T. Rowe Price Investment Management, Inc.6.6%
Goldman Sachs Group Inc4.6%
T. Rowe Price Associates3.4%
BlackRock, Inc.2.4%
Nan Fung Group Holdings Ltd2.3%
5AM Venture Management, LLC2.2%
Sanofi2.1%
State Street Corp2.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Novo Holdings A/s3.69M8.69%$132MNo change
Fcpm III Services B.v.3.23M7.60%$116MNo change
T. Rowe Price Investment Management, Inc.2.78M6.56%$99.7M-1%
Goldman Sachs Group Inc1.95M4.59%$69.8M-2%
T. Rowe Price Associates1.42M3.35%$51M+1162%
BlackRock, Inc.1.03M2.42%$36.7M-23%
Nan Fung Group Holdings Ltd971,2532.29%$34.8MNo change
5AM Venture Management, LLC950,0112.24%$34MNo change
Sanofi912,0412.15%$32.7MNo change
State Street Corp852,1502.01%$30.5M+151%
FMR LLC (Fidelity)823,5561.94%$29.5M+303%
Vanguard Capital Management LLC784,1501.85%$28.1M+9%
Blue Owl Capital Holdings LP729,9291.72%$26.2M-27%
Paradigm Biocapital Advisors LP685,8521.62%$24.6MNew
Pivotal bioVenture Partners Investment Advisor LLC611,4461.44%$21.9MNo change
Velan Capital Investment Management LP492,8931.16%$17.7MNo change
Siren, L.L.C.450,0001.06%$16.1MNo change
Capital World Investors415,7300.98%$14.9MNew
Geode Capital Management, LLC402,0510.95%$14.4M-16%
Baker Bros. Advisors LP364,7050.86%$13.1MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MPLT insiders reported $66.2M of open-market purchases and $30.2M of sales. 66% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$66.2M
10 trades, 4 people
Sales, 12 months
$30.2M
145 trades, 8 people
Sales under a 10b5-1 plan
66%
Share of sale value
Latest trade
Oct 15, 2026
Filed Oct 16, 2026

Purchases and sales by month

$50.1M$50.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 15, 2026Erin Pennock FoffChief Medical OfficerSale15,355$8.08$124KForm 4
Oct 15, 2026Jonathan GillisCFOSale10,167$8.08$82.1KForm 4
Oct 15, 2026Kristopher HansonGeneral CounselSale9,020$8.08$72.9KForm 4
Oct 15, 2026Anatol KreitzerChief Discovery OfficerSale12,248$7.84$96KForm 4
Oct 15, 2026Christopher A. KroegerCEOSale73,691$8.08$595KForm 4
Oct 15, 2026James Woodruff LillieChief Scientific OfficerSale11,513$8.08$93KForm 4
Sep 16, 2026Kristopher HansonGeneral CounselSale plan16,509$11.67$193KForm 4
Aug 14, 2026Catalyst4, Inc.10% ownerPurchase4.40M$11.38$50.1MForm 4
Aug 3, 2026James Woodruff LillieChief Scientific OfficerSale plan22,082$12.54$277KForm 4
Jul 30, 2026Catalyst4, Inc.10% ownerPurchase1.00M$13.00$13MForm 4
Jul 29, 2026Catalyst4, Inc.10% ownerPurchase3,000$12.63$37.9KForm 4
Jul 28, 2026Catalyst4, Inc.10% ownerPurchase65,137$11.69$761KForm 4
Jul 28, 2026Catalyst4, Inc.10% ownerPurchase141,088$10.74$1.5MForm 4
Jul 28, 2026Troy CoxDirectorPurchase15,620$9.52$149KForm 4
Jul 17, 2026Jonathan GillisCFOSale plan16,969$37.61$638KForm 4
Jul 17, 2026Jonathan GillisCFOSale plan600$36.51$21.9KForm 4
Jul 17, 2026Jonathan GillisCFOSale plan900$38.17$34.4KForm 4
Jul 17, 2026Anatol KreitzerChief Discovery OfficerSale plan200$38.39$7.7KForm 4
Jul 17, 2026Anatol KreitzerChief Discovery OfficerSale plan14,140$37.70$533KForm 4
Jul 17, 2026Anatol KreitzerChief Discovery OfficerSale plan2,833$37.05$105KForm 4
Jul 17, 2026Christopher A. KroegerCEOSale16,779$37.90$636KForm 4
Jul 17, 2026James Woodruff LillieChief Scientific OfficerSale2,077$37.90$78.7KForm 4
Jul 17, 2026Kristopher HansonGeneral CounselSale1,130$37.90$42.8KForm 4
Jul 17, 2026Erin Pennock FoffChief Medical OfficerSale plan3,656$37.90$139KForm 4
Jul 16, 2026Jonathan GillisCFOSale plan6,979$36.66$256KForm 4
Jul 16, 2026Jonathan GillisCFOSale plan1,476$37.44$55.3KForm 4
Jul 16, 2026Anatol KreitzerChief Discovery OfficerSale plan1,592$37.44$59.6KForm 4
Jul 16, 2026Anatol KreitzerChief Discovery OfficerSale plan7,464$36.66$274KForm 4
Jul 16, 2026Christopher A. KroegerCEOSale28,091$37.26$1MForm 4
Jul 16, 2026Christopher A. KroegerCEOSale92$37.96$3.5KForm 4
Jul 16, 2026Christopher A. KroegerCEOSale40,899$36.46$1.5MForm 4
Jul 16, 2026James Woodruff LillieChief Scientific OfficerSale12$37.96$456Form 4
Jul 16, 2026James Woodruff LillieChief Scientific OfficerSale3,526$37.26$131KForm 4
Jul 16, 2026James Woodruff LillieChief Scientific OfficerSale5,009$36.45$183KForm 4
Jul 16, 2026Kristopher HansonGeneral CounselSale3,331$37.26$124KForm 4
Jul 16, 2026Kristopher HansonGeneral CounselSale4,776$36.45$174KForm 4
Jul 16, 2026Kristopher HansonGeneral CounselSale11$37.96$418Form 4
Jul 16, 2026Erin Pennock FoffChief Medical OfficerSale plan19$37.96$721Form 4
Jul 16, 2026Erin Pennock FoffChief Medical OfficerSale plan5,865$37.26$219KForm 4
Jul 16, 2026Erin Pennock FoffChief Medical OfficerSale plan9,163$36.46$334KForm 4
Jul 15, 2026Jonathan GillisCFOSale plan5,356$36.13$194KForm 4
Jul 15, 2026Jonathan GillisCFOSale plan4,699$36.94$174KForm 4
Jul 15, 2026Anatol KreitzerChief Discovery OfficerSale plan4,510$36.94$167KForm 4
Jul 15, 2026Anatol KreitzerChief Discovery OfficerSale plan5,545$36.13$200KForm 4
Jul 15, 2026Christopher A. KroegerCEOSale18,950$36.00$682KForm 4
Jul 15, 2026Christopher A. KroegerCEOSale42,738$36.99$1.6MForm 4
Jul 15, 2026Christopher A. KroegerCEOSale90$37.54$3.4KForm 4
Jul 15, 2026James Woodruff LillieChief Scientific OfficerSale5,393$36.99$199KForm 4
Jul 15, 2026James Woodruff LillieChief Scientific OfficerSale12$37.54$450Form 4
Jul 15, 2026James Woodruff LillieChief Scientific OfficerSale2,238$36.00$80.6KForm 4
Jul 15, 2026Kristopher HansonGeneral CounselSale5,103$36.99$189KForm 4
Jul 15, 2026Kristopher HansonGeneral CounselSale2,147$36.00$77.3KForm 4
Jul 15, 2026Kristopher HansonGeneral CounselSale10$37.54$375Form 4
Jul 15, 2026Erin Pennock FoffChief Medical OfficerSale plan4,465$36.00$161KForm 4
Jul 15, 2026Erin Pennock FoffChief Medical OfficerSale plan8,972$36.99$332KForm 4
Jul 15, 2026Erin Pennock FoffChief Medical OfficerSale plan7,845$37.04$291KForm 4
Jul 15, 2026Erin Pennock FoffChief Medical OfficerSale plan7,155$36.16$259KForm 4
Jul 15, 2026Erin Pennock FoffChief Medical OfficerSale plan18$37.54$676Form 4
May 18, 2026Christopher A. KroegerCEOSale plan198$28.15$5.6KForm 4
May 18, 2026Christopher A. KroegerCEOSale plan118,037$27.19$3.2MForm 4
May 11, 2026Kristopher HansonGeneral CounselSale plan5,808$30.56$177KForm 4
May 11, 2026Kristopher HansonGeneral CounselSale plan6,979$30.04$210KForm 4
May 11, 2026Kristopher HansonGeneral CounselSale plan846$28.70$24.3KForm 4
May 11, 2026Kristopher HansonGeneral CounselSale plan284$27.61$7.8KForm 4
May 11, 2026Christopher A. KroegerCEOSale plan877$28.70$25.2KForm 4
May 11, 2026Christopher A. KroegerCEOSale plan6,871$30.04$206KForm 4
May 11, 2026Christopher A. KroegerCEOSale plan5,890$30.56$180KForm 4
May 11, 2026Christopher A. KroegerCEOSale plan342$27.57$9.4KForm 4
May 8, 2026Christopher A. KroegerCEOSale plan1,582$28.56$45.2KForm 4
May 8, 2026Christopher A. KroegerCEOSale plan29,624$27.48$814KForm 4
May 8, 2026Christopher A. KroegerCEOSale plan3,205$29.20$93.6KForm 4
May 7, 2026Christopher A. KroegerCEOSale plan5,220$29.15$152KForm 4
May 7, 2026Christopher A. KroegerCEOSale plan14,880$28.47$424KForm 4
May 7, 2026Erin Pennock FoffChief Medical OfficerSale plan4,321$28.52$123KForm 4
May 7, 2026Erin Pennock FoffChief Medical OfficerSale plan117$29.10$3.4KForm 4
May 7, 2026James Woodruff LillieChief Scientific OfficerSale plan721$28.28$20.4KForm 4
May 6, 2026Vishwas SetiaCFOSale plan8,496$28.04$238KForm 4
May 6, 2026Vishwas SetiaCFOSale plan2,068$29.07$60.1KForm 4
May 6, 2026Erin Pennock FoffChief Medical OfficerSale plan8,152$28.04$229KForm 4
May 6, 2026Erin Pennock FoffChief Medical OfficerSale plan15,900$29.13$463KForm 4
May 6, 2026James Woodruff LillieChief Scientific OfficerSale plan16,421$29.13$478KForm 4
May 6, 2026James Woodruff LillieChief Scientific OfficerSale plan8,390$28.04$235KForm 4
May 6, 2026Christopher A. KroegerCEOSale plan15,603$29.13$455KForm 4
May 6, 2026Christopher A. KroegerCEOSale plan8,098$28.04$227KForm 4
May 5, 2026Vishwas SetiaCFOSale plan9,935$28.12$279KForm 4
May 5, 2026Vishwas SetiaCFOSale plan968$29.00$28.1KForm 4
May 5, 2026Erin Pennock FoffChief Medical OfficerSale plan9,645$28.12$271KForm 4
May 5, 2026Erin Pennock FoffChief Medical OfficerSale plan931$29.00$27KForm 4
May 5, 2026James Woodruff LillieChief Scientific OfficerSale plan963$29.00$27.9KForm 4
May 5, 2026James Woodruff LillieChief Scientific OfficerSale plan10,132$28.12$285KForm 4
May 5, 2026Christopher A. KroegerCEOSale plan9,544$28.12$268KForm 4
May 5, 2026Christopher A. KroegerCEOSale plan928$29.00$26.9KForm 4
May 4, 2026Vishwas SetiaCFOSale plan4,803$27.36$131KForm 4
May 4, 2026Vishwas SetiaCFOSale plan8,989$28.28$254KForm 4
May 4, 2026Vishwas SetiaCFOSale plan325$29.56$9.6KForm 4
May 4, 2026Vishwas SetiaCFOSale plan787$30.12$23.7KForm 4
May 4, 2026Erin Pennock FoffChief Medical OfficerSale plan9,180$27.50$252KForm 4
May 4, 2026Erin Pennock FoffChief Medical OfficerSale plan5,460$28.37$155KForm 4
May 4, 2026Erin Pennock FoffChief Medical OfficerSale plan312$29.56$9.2KForm 4
May 4, 2026Erin Pennock FoffChief Medical OfficerSale plan700$30.08$21.1KForm 4

Latest 100 of 155 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Catalyst4, Inc.10% owner$65.4M–Aug 14, 2026
Christopher A. KroegerChief Executive Officer, Director–$13.1MOct 15, 2026
Jonathan GillisCAAO and PAO–$3.6MOct 15, 2026
Erin Pennock FoffChief Medical Officer–$3.5MOct 15, 2026
Anatol KreitzerChief Discovery Officer–$2.9MOct 15, 2026
James Woodruff LillieChief Scientific Officer–$2.7MOct 15, 2026
Kristopher HansonGeneral Counsel–$1.7MOct 15, 2026
Robert C. MalenkaDirector–$1.6MApr 15, 2026
Vishwas SetiaChief Financial Officer–$1.1MMay 6, 2026
George PavlovDirector$441K–Feb 20, 2026
Timothy John GarnettDirector$253K–Feb 10, 2026
Troy CoxDirector$149K–Jul 28, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MPLT short interest

3.25M MPLT shares are sold short. Over the last 12 reports the number of shares short went up 139%.

As of Oct 30, 2026, 3.25M MPLT shares were sold short, down 2.1% from the report before. At the average daily volume of 315,511 shares, buying them all back would take about 10.3 trading days (days to cover).

Shares short, % of all shares

7.42%May 15Sep 309.24%

Days to cover

10.3May 15Oct 3011.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.25M–-2%315,51110.3
Oct 15, 20263.32M–+6%399,4248.3
Sep 30, 20263.15M7.42%-5%542,9755.8
Sep 15, 20263.30M7.77%-4%542,8496.1
Aug 31, 20263.43M8.07%+6%601,1425.7
Aug 14, 20263.24M7.63%-10%589,8305.5
Jul 31, 20263.58M8.44%-0%2.17M1.6
Jul 15, 20263.59M8.45%+39%533,9846.7
Jun 30, 20262.58M6.07%+36%637,6554.0
Jun 15, 20261.90M4.48%+22%291,9556.5
May 29, 20261.56M3.68%+15%291,3905.4
May 15, 20261.36M3.21%-22%243,2805.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

MapLight Therapeutics company events

MapLight Therapeutics filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 13, 2026.

  1. Aug 13, 2026AgreementMapLight Therapeutics, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (i) 9,197,887 shares of the Company’s voting common stock, par value $0.0001 per… Filing
  2. Jul 27, 2026AnnouncementThe Company issued a press release announcing the ZEPHYR Trial Results. Filing
  3. Jun 24, 2026VoteReported shareholder vote results. Filing
  4. Jun 22, 2026AnnouncementThe Company issued a press release announcing the IRIS Trial Results. Filing
  5. Jun 18, 2026LeadershipVishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc., effective immediately, following a review of a human resources violation. Filing
  6. May 14, 2026ResultsReleased financial results. Filing
  7. Apr 29, 2026LeadershipRobert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors of MapLight Therapeutics, Inc. of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026. Filing
  8. Mar 26, 2026ResultsReleased financial results. Filing
  9. Jan 9, 2026ResultsReleased financial results. Filing
  10. Dec 4, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

MapLight Therapeutics financials

Famous investors that hold MPLT

3 of the 50 well-known investors we track reported holding MPLT in their latest 13F filing. The largest position is Steve Cohen's, worth $4.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026426,261$4.3M0.0%New
Israel Englander · Millennium ManagementQ3 2026423,678$4.3M0.0%+229%
Ken Griffin · Citadel AdvisorsQ3 202685,475$871K0.0%+232%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MPLT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Forbion Growth Opportunities Fund III Cooperatief U.A.13G/A8.4%
Nov 16, 2026Forbion Growth Opportunities Fund III Cooperatief U.A.13G/A8.4%
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G/A1.7%
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G/A1.7%

Questions about MapLight Therapeutics, Inc. (MPLT) stock

Who owns the most MPLT stock?

The largest reported owner of MapLight Therapeutics, Inc. (MPLT) is Novo Holdings A/s, with 8.7% of the company. In total, 107 funds and institutions reported holding MPLT at the end of Q2 2026, together about 62% of the shares. See the largest owners.

Are MPLT insiders buying or selling?

In the last 12 months, MPLT insiders reported 10 open-market purchases worth $66.2M and 145 sales worth $30.2M. The latest trade was on Oct 15, 2026. See every trade.

What is the short interest in MPLT?

As of Oct 30, 2026, 3.25M MPLT shares were sold short, down 2.1% from the report before. At the average daily volume of 315,511 shares, buying them all back would take about 10.3 trading days (days to cover). See the history.

Which famous investors hold MPLT?

3 of the 50 well-known investors we track reported MPLT in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $4.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.